A case of refractory chronic spontaneous urticaria treated with omalizumab

Authors

  • Humayun Shahzad Clinic, Fauji Fertilizer Company, Sadiqabad

DOI:

https://doi.org/10.66344/jpad.26.3.2016.39

Keywords:

Chronic spontaneous urticaria, omalizumab

Abstract

Chronic spontaneous urticaria (CSU) is a chronic and refractory dermatosis. Omalizumab is a relatively new addition to CSU therapeutic armamentarium. We present a 52-year-old male having symptoms of chronic spontaneous urticaria (CSU) of moderate severity for last 15 years. He was on regular H1 antagonist and mast cell stabilizers was started with 300 mg omalizumab on monthly basis, Urticaria activity score started improving after second month. Patient is still using H1 antagonist but not regularly but with a liberal lifestyle as compared to previously.

References

Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007;120:979-81.

Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol. 2007;99:190-3.

Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122:569-73.

Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM et al. EAACI/GA2LEN/ EDF guideline: management of urticaria. Allergy. 2006;61:321-31.

Downloads

Published

2017-03-29

How to Cite

1.
Shahzad H. A case of refractory chronic spontaneous urticaria treated with omalizumab. J Pak Assoc Dermatol [Internet]. 2017Mar.29 [cited 2026Apr.21];26(3):276-8. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/39

Issue

Vol. 26 No. 3 (2016): July - September

Section

Case Reports

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.